SNTI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	44 695.00
Average Volume	79 506.00
Market Cap	13.27M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.230 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0.00300 (1.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Rajangam Kanya	Buy	152 000	Stock Option (Right to Buy)
2024-02-01	Rajangam Kanya	Buy	101 000	Common Stock
2024-02-01	Lu Timothy K	Buy	306 000	Common Stock
2024-02-01	Lu Timothy K	Buy	459 000	Stock Option (Right to Buy)
2024-02-01	Knobelman Deborah	Buy	152 000	Stock Option (Right to Buy)

INSIDER POWER
-3.78
Last 75 transactions
Buy: 10 399 991 \| Sell: 33 461 793

Senti Biosciences, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Senti Biosciences, Inc. Financials

Annual	2023
Revenue:	$2.56M
Gross Profit:	$-2.68M (-104.76 %)
EPS:	$-2.09

FY	2023
Revenue:	$2.56M
Gross Profit:	$-2.68M (-104.76 %)
EPS:	$-2.09

FY	2022
Revenue:	$4.29M
Gross Profit:	$366 000 (8.54 %)
EPS:	$-1.750

FY	2021
Revenue:	$2.29M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.267

Financial Reports:

No articles found.

Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.